🧠 Esketamine + Antidepressants in TRD: Does the Combo Matter?

📢 New data from a real-world study of 50,000+ patients with treatment-resistant depression (TRD) published in JAMA Psychiatry:

📌 Study Question:
Does combining esketamine with an SSRI or SNRI affect long-term outcomes in TRD?

📊 Key Findings (5-Year Follow-Up):

• ✅ Esketamine + SNRI:
   ↘️ Lower all-cause mortality
   ↘️ Fewer hospitalizations
   ↘️ Reduced depressive relapse
• ✅ Esketamine + SSRI:
   ↘️ Lower incidence of suicide attempts
• 🔒 Overall: Low rates of adverse outcomes in all groups

💡 Clinical Implications:

• Not all combinations are equal—pairing matters.
• Esketamine + SNRI may be preferred for reducing relapse/mortality
• Esketamine + SSRI may be considered in patients at risk for suicide
• Personalized treatment decisions can enhance outcomes in TRD

🔍 More than symptom relief—it’s about survival, stability, and safety.